Enliven Therapeutics Revenue and Competitors

Boulder, CO USA

Location

#2799

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Enliven Therapeutics's estimated annual revenue is currently $10.2M per year.(i)
  • Enliven Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Enliven Therapeutics has 66 Employees.(i)
  • Enliven Therapeutics grew their employee count by 50% last year.

Enliven Therapeutics's People

NameTitleEmail/Phone
1
Co-founder, Chief Scientific Officer and Member the Board DirectorsReveal Email/Phone
2
Co-Founder and CEOReveal Email/Phone
3
Co-Founder and COOReveal Email/Phone
4
Chief Legal Officer and Head Business DevelopmentReveal Email/Phone
5
VP Clinical OperationsReveal Email/Phone
6
VP, Head Clinical PharmacologyReveal Email/Phone
7
VP CMCReveal Email/Phone
8
VP, Head BiometricsReveal Email/Phone
9
VP BiologyReveal Email/Phone
10
VP, Finance & AccountingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.2M453-1%N/AN/A
#4
$1.6M10-66%N/AN/A
#5
$3.7M24-8%N/AN/A
#6
$2.9M3728%N/AN/A
#7
$3.1M2025%N/AN/A
#8
$2.5M16-20%N/AN/A
#9
$9.1M590%N/AN/A
#10
$4.2M27-7%N/AN/A
Add Company

What Is Enliven Therapeutics?

Advancing Medicine, Restoring Lives Enliven Therapeutics is a biotechnology company focusing on the discovery and development of next generation precision oncology therapeutics. We are advancing cancer treatment by improving upon scientific advancements to address cancer's unmet needs. The Enliven team of industry-leading chemists and biologists—collaborating with top-tier advisors—are committed to our mission: to help patients with cancer to not only live longer, but live better.

keywords:N/A

N/A

Total Funding

66

Number of Employees

$10.2M

Revenue (est)

50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.4M6620%N/A
#2
$12.2M66-4%N/A
#3
$16.3M6729%N/A
#4
$19.5M678%N/A
#5
$9.6M6763%N/A